Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr14.04 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr575.51M
Enterprise Valuekr576.03
Total Cash (Recent Filing)kr276.90M
Total Debt (Recent Filing)kr9.90M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Oct 22, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.87
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.03
Revenue Forecast (FY)kr26.00M
Bulls Say, Bears Say
Bulls Say
Improved SolvencyTrailing-twelve-month leverage has materially improved, leaving Orexo with very low reported debt versus equity. Lower structural leverage reduces refinancing and interest risks, giving management more optionality to fund development, negotiate partnerships, and withstand regulatory or commercial delays over the next 2–6 months.
Positive Operating/free Cash FlowA shift to positive operating and free cash flow on a TTM basis is a durable improvement in cash generation versus prior multi-year burn. This reduces immediate financing pressure, helps preserve runway for clinical programs, and supports business development or milestone-driven funding over the medium term if cash conversion remains stable.
Strong IP And Platform ValueLong-dated exclusivity for OX640 (to 2044) and potential GLP-1 extensions (to 2047), plus the AmorphOX thermostability platform, create durable competitive assets. These structural IP advantages support long-term licensing, premium pricing potential, and partner interest for biologics/vaccine programs, underpinning multi-year commercial optionality.
Bears Say
Persistent UnprofitabilityThe core business remains structurally loss-making with negative gross profit and steep operating and net margins. Sustained losses erode shareholder equity generation, limit reinvestment capacity, and make the company reliant on external financing or partnerships to fund growth, representing a multi-month durability risk until commercial margins recover.
Ongoing DOJ Legal UncertaintyAn unresolved DOJ investigation is a structural overhang that can drive litigation costs, potential settlement payments, and insurance reliance. This uncertainty impairs financing flexibility, complicates partner negotiations and long-term planning, and may require multi-quarter legal spend and contingency planning until a definitive resolution is reached.
High Near-term Development Spend And Cash BurnMaterial quarter-on-quarter cash burn combined with a flagged SEK ~200m external cost envelope for OX640 concentrates funding needs in H2 2027–H1 2028. Unless partners assume costs or additional financing is secured, this structural spending profile risks shortening runway, increasing dilution risk, or forcing program timing changes over the coming 2–6 months.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr14.04 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr575.51M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 91 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -kr2.2 earnings per share for the quarter, missing the consensus estimate of -kr1.6 by -kr0.6.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -2.1.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr2.2 in its last earnings report, missing expectations of -kr1.6. Following the earnings report the stock price went down -16.279%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―